Physician profile
Dana E Blasko
NPI 1184786592
$5,084.29
in general payments reported to CMS, 2019-2025
23 companies · $1,711 in 2025
The $1,711 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $697 · 2022: $906 · 2023: $788 · 2024: $983 · 2025: $1,711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,460 · Consulting Fee: $21.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,459.60 |
| Consulting Fee | $21.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,127.98 | 2021-2025 | Airsupra, Fasenra, Tezspire |
| Genzyme Corporation | $737.29 | 2021-2025 | |
| Glaxosmithkline, LLC. | $696.09 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $500.83 | 2021-2025 | Hyqvia, Takhzyro |
| Csl Behring | $260.84 | 2021-2025 | Hizentra |
| Novartis Pharmaceuticals Corporation | $201.15 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $187.74 | 2023-2025 | Dupixent |
| Alk-Abello, INC | $167.39 | 2021-2025 | Grastek, Odactra, Ragwitek |
| Ars Pharmaceuticals Operations, INC. | $147.22 | 2025 | Neffy |
| Kaleo, INC. | $139.24 | 2021-2024 | Auvi-Q |
| Optinose US, INC. | $123.01 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.93 | 2021-2022 | |
| Amgen INC. | $120.34 | 2022-2024 | Tezspire |
| Octapharma USA, INC. | $91.22 | 2021-2024 | Panzyga |
| Grifols USA, LLC | $79.69 | 2025 | Prolastin-C Liquid, Xembify |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $76.94 | 2022-2025 | Orladeyo |
| Genentech USA, INC. | $75.06 | 2024-2025 | Xolair |
| Pfizer INC. | $71.25 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $52.96 | 2021-2022 | |
| Abbvie INC. | $37.87 | 2023-2024 | |
| Pharming Healthcare, INC. | $23.77 | 2022 | |
| Bio Products Laboratory USA, INC. | $22.06 | 2021 | |
| Adma Biomanufacturing LLC | $21.42 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Blasko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.